Roskos LK[au] - Search Results

Year	Number of Results
1990	1
1993	1
1996	2
2000	3
2001	4
2002	1
2004	2
2006	2
2007	3
2010	1
2011	1
2012	2
2013	4
2014	2
2015	5
2016	4
2017	3
2018	6
2019	4
2020	5
2021	1
2022	1

1

Elimination mechanisms of therapeutic monoclonal antibodies.

Tabrizi MA, Tseng CM, Roskos LK. Tabrizi MA, et al. Among authors: roskos lk. Drug Discov Today. 2006 Jan;11(1-2):81-8. doi: 10.1016/S1359-6446(05)03638-X. Drug Discov Today. 2006. PMID: 16478695 Review.

2

Preclinical and clinical safety of monoclonal antibodies.

Tabrizi MA, Roskos LK. Tabrizi MA, et al. Among authors: roskos lk. Drug Discov Today. 2007 Jul;12(13-14):540-7. doi: 10.1016/j.drudis.2007.05.010. Epub 2007 Jun 27. Drug Discov Today. 2007. PMID: 17631248 Review.

3

PK-PD modeling of protein drugs: implications in assay development.

Roskos LK, Schneider A, Vainshtein I, Schwickart M, Lee R, Lu H, Faggioni R, Liang M. Roskos LK, et al. Bioanalysis. 2011 Mar;3(6):659-75. doi: 10.4155/bio.11.28. Bioanalysis. 2011. PMID: 21417734 Review.

4

Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development.

Liang M, Schwickart M, Schneider AK, Vainshtein I, Del Nagro C, Standifer N, Roskos LK. Liang M, et al. Among authors: roskos lk. Cytometry B Clin Cytom. 2016 Mar;90(2):117-27. doi: 10.1002/cyto.b.21259. Epub 2015 Jul 31. Cytometry B Clin Cytom. 2016. PMID: 26054054 Free PMC article. Review.

5

Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma.

Arends R, Guo X, Baverel PG, González-García I, Xie J, Morsli N, Yovine A, Roskos LK. Arends R, et al. Among authors: roskos lk. Oncoimmunology. 2021 Mar 17;10(1):1898104. doi: 10.1080/2162402X.2021.1898104. Oncoimmunology. 2021. PMID: 33796405 Free PMC article.

6

Confirmatory cut point has limited ability to make accurate classifications in immunogenicity assays.

Kubiak RJ, Arends RH, Lee N, Liang M, Zhang J, Roskos LK. Kubiak RJ, et al. Among authors: roskos lk. Bioanalysis. 2020 Feb;12(4):245-256. doi: 10.4155/bio-2019-0283. Epub 2020 Feb 24. Bioanalysis. 2020. PMID: 32090586 Free article.

7

A new method for identification of outliers in immunogenicity assay cut point data.

Zhang J, Arends RH, Kubiak RJ, Roskos LK, Liang M, Lee N, Chen CC, Yang H. Zhang J, et al. Among authors: roskos lk. J Immunol Methods. 2020 Sep-Oct;484-485:112817. doi: 10.1016/j.jim.2020.112817. Epub 2020 Jun 29. J Immunol Methods. 2020. PMID: 32615125

8

Molecular Mechanism of HER2 Rapid Internalization and Redirected Trafficking Induced by Anti-HER2 Biparatopic Antibody.

Cheng J, Liang M, Carvalho MF, Tigue N, Faggioni R, Roskos LK, Vainshtein I. Cheng J, et al. Among authors: roskos lk. Antibodies (Basel). 2020 Sep 18;9(3):49. doi: 10.3390/antib9030049. Antibodies (Basel). 2020. PMID: 32961882 Free PMC article.

9

Immunogenicity assay cut point determination using nonparametric tolerance limit.

Zhang J, Li W, Roskos LK, Yang H. Zhang J, et al. Among authors: roskos lk. J Immunol Methods. 2017 Mar;442:29-34. doi: 10.1016/j.jim.2017.01.001. Epub 2017 Jan 5. J Immunol Methods. 2017. PMID: 28063769

10

Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody.

Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, Rowinsky EK, Dutcher JP, Vogelzang NJ, Gollub J, Thompson JA, Schwartz G, Bukowski RM, Roskos LK, Schwab GM. Foon KA, et al. Among authors: roskos lk. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):984-90. doi: 10.1016/j.ijrobp.2003.09.098. Int J Radiat Oncol Biol Phys. 2004. PMID: 14967460 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results